文献速递慢性肾脏病遗传性与小管间质肾病水电解质与酸碱

原发性高草酸尿症临床试验终点的确定

End Points for Clinical Trials in Primary Hyperoxaluria.
PubMed 文献 · Clin J Am Soc Nephrol · 2020-03-12

原发性高草酸尿症患者早年即出现肾结石,并可进展为草酸盐肾病和肾衰竭,目前尚无获批疗法。肾脏健康倡议与草酸盐增多症基金会合作,召集多学科工作组批判性审查文献,识别临床试验终点。肾结石、eGFR变化、尿草酸盐和血浆草酸盐是最强候选终点;eGFR斜率变化可支持传统批准,尿草酸盐显著变化可支持1型原发性高草酸尿症且CKD 1-3a期患者的传统批准,血浆草酸盐显著变化可支持CKD 3b-5期患者的加速批准。

要点

  • eGFR斜率变化可作为临床有意义的终点支持传统批准。
  • 尿草酸盐显著变化可作为1型原发性高草酸尿症且CKD 1-3a期的替代终点。
  • 血浆草酸盐显著变化可支持CKD 3b-5期患者的加速批准。

核心结论

  • 肾结石、eGFR变化、尿草酸盐和血浆草酸盐是原发性高草酸尿症临床试验的最强候选终点。

研究设计与样本

  • 肾脏健康倡议与草酸盐增多症基金会合作,召集医生、科学家、患者、产业界和美国监管机构组成工作组,批判性审查已发表文献。

主要发现

  • 肾结石影响患者感受和功能,但缺乏测量和监测标准。
  • 注册数据提示多数患者eGFR下降缓慢但不可预测。
  • 流行病学数据显示尿草酸盐与长期肾功能丧失强相关。

关键数值与推荐

  • eGFR斜率变化可视为等同于临床有意义的终点以支持传统批准。
  • 尿草酸盐显著变化作为替代终点可支持1型原发性高草酸尿症且CKD 1-3a期患者的传统批准。
  • 血浆草酸盐显著变化可支持原发性高草酸尿症且CKD 3b-5期患者的加速批准。

临床怎么用

  • 临床试验可考虑eGFR斜率变化作为传统批准终点。
  • 1型原发性高草酸尿症且CKD 1-3a期患者可用尿草酸盐显著变化作为替代终点。
  • CKD 3b-5期患者可用血浆草酸盐显著变化作为加速批准终点。

局限性

  • 1型原发性高草酸尿症占可用数据的绝大多数,严重影响结论。
  • 肾结石的测量和监测标准缺乏。
  • eGFR下降在多数患者中缓慢但不可预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with primary hyperoxaluria experience kidney stones from a young age and can develop progressive oxalate nephropathy. Progression to kidney failure often develops over a number of years, and is associated with systemic oxalosis, intensive dialysis, and often combined kidney and liver transplantation. There are no therapies approved by the Food and Drug Association. Thus, the Kidney Health Initiative, in partnership with the Oxalosis and Hyperoxaluria Foundation, initiated a project to identify end points for clinical trials. A workgroup of physicians, scientists, patients with primary hyperoxaluria, industry, and United States regulators critically examined the published literature for clinical outcomes and potential surrogate end points that could be used to evaluate new treatments. Kidney stones, change in eGFR, urine oxalate, and plasma oxalate were the strongest candidate end points. Kidney stones affect how patients with primary hyperoxaluria feel and function, but standards for measurement and monitoring are lacking. Primary hyperoxaluria registry data suggest that eGFR decline in most patients is gradual, but can be unpredictable. Epidemiologic data show a strong relationship between urine oxalate and long-term kidney function loss. Urine oxalate is reasonably likely to predict clinical benefit, due to its causal role in stone formation and kidney damage in CKD stages 1-3a, and plasma oxalate is likely associated with risk of systemic oxalosis in CKD 3b-5. Change in slope of eGFR could be considered the equivalent of a clinically meaningful end point in support of traditional approval. A substantial change in urine oxalate as a surrogate end point could support traditional approval in patients with primary hyperoxaluria type 1 and CKD stages 1-3a. A substantial change in markedly elevated plasma oxalate could support accelerated approval in patients with primary hyperoxaluria and CKD stages 3b-5. Primary hyperoxaluria type 1 accounts for the preponderance of available data, thus heavily influences the conclusions. Addressing gaps in data will further facilitate testing of promising new treatments, accelerating improved outcomes for patients with primary hyperoxaluria.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Milliner DS, McGregor TL, Thompson A, et al. End Points for Clinical Trials in Primary Hyperoxaluria. Clin J Am Soc Nephrol. 2020. PMID: 32165440. doi:10.2215/CJN.13821119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。